METHYLPREDNISOLONE HEMISUCCINATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H34O8
Molecular Weight	474.5434
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of METHYLPREDNISOLONE HEMISUCCINATE

Structure Search

SMILES

[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])C[C@H](C)C4=CC(=O)C=C[C@]34C

InChI

InChIKey=IMBXEJJVJRTNOW-XYMSELFBSA-N

InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H34O8
Molecular Weight	474.5434
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00959
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/medrol.html

Methylprednisolone is a prednisolone derivative with similar anti-inflammatory and immunosuppressive action. It is adjunctive therapy for short-term administration in rheumatoid arthritis. It is indicated in the following conditions: endocrine disorders, rheumatic disorders, collagen diseases, allergic states etc. Methylprednisolone is marketed in the USA and Canada under the brand names Medrol and Solu-Medrol. Methylprednisolone is a GR receptor agonist.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Glucocorticoid receptor 172 Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00959	Agonist 2678	2.4 nM [EC50]
Glucocorticoid receptor 172 Target ID: CHEMBL2034 Sources: http://www.ampoule.org.hk/pdf/advantan.pdf	Agonist 2678
Serotonin 3 (5-HT3) receptor 59 Target ID: CHEMBL2111332 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15329590	Inhibitor 8297	1.07 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Congenital adrenal hyperplasia 41 Sources: https://www.drugs.com/pro/medrol.html	Primary	Approved 8429	MEDROL Approved Use INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. Launch Date 1957
Rheumatoid arthritis 316 Sources: https://www.drugs.com/pro/medrol.html	Primary	Approved 8429	MEDROL Approved Use INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. Launch Date 1957
Contact dermatitis 20 Sources: https://www.drugs.com/pro/medrol.html	Primary	Approved 8429	MEDROL Approved Use INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. Launch Date 1957

C_max

Value	Dose	Co-administered	Analyte	Population
213 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030	32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered:		METHYLPREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
931 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030	32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered:		METHYLPREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.3 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030	32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered:		METHYLPREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
23% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/?term=3732369			METHYLPREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1000 mg/kg single, intravenous Highest studied dose Dose: 1000 mg/kg Route: intravenous Route: single Dose: 1000 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/8107739	unhealthy, 0-15 years n = 26 Health Status: unhealthy Condition: sickle cell disease Age Group: 0-15 years Sex: M+F Population Size: 26 Sources: https://pubmed.ncbi.nlm.nih.gov/8107739	Sources: https://pubmed.ncbi.nlm.nih.gov/8107739
1250 mg 1 times / day multiple, oral Highest studied dose Dose: 1250 mg, 1 times / day Route: oral Route: multiple Dose: 1250 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30351511	unhealthy, 18–59 years n = 24 Health Status: unhealthy Condition: multiple sclerosis relapse Age Group: 18–59 years Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/30351511	Sources: https://pubmed.ncbi.nlm.nih.gov/30351511
120 mg 1 times / week multiple, intramuscular Highest studied dose Dose: 120 mg, 1 times / week Route: intramuscular Route: multiple Dose: 120 mg, 1 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/011757s119lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/011757s119lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/011757s119lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inducer 781

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
SLC10A2 9	11-beta-HSD2 27 11-beta-HSD1 12 AKR1C1 19	P-gp 257

Drug as perpetrator

Target	Modality	Activity
SLC10A2 9	inhibitor 3277 Sources: https://pubs.acs.org/doi/abs/10.1021/mp900163d Page: -	no
CYP3A4 1925	inducer 1573 Sources: https://link.springer.com/article/10.1007/s00204-008-0332-8 Page: -	yes
P-gp 1650	inducer 1573 Sources: https://www.sciencedirect.com/science/article/pii/S0378427411015943 Page: -	yes

Drug as victim

Target	Modality	Activity
11-beta-HSD1 12	substrate 3367 Sources: https://academic.oup.com/jcem/article/87/12/5695/2823639 Page: -	yes
11-beta-HSD2 27	substrate 3367 Sources: https://academic.oup.com/jcem/article/87/12/5695/2823639 Page: -	yes
AKR1C1 19	substrate 3367 Sources: http://epubs.surrey.ac.uk/855783/1/27606608.pdf Page: -	yes
CYP3A4 1737	substrate 3367 Sources: https://link.springer.com/article/10.1007/s00228-009-0653-4 Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-004636	http://www.3bsc.com/index/pro_info.php?id=26522
AA Blocks	AA003AUL	https://www.aablocks.com/goods/Goods/detail?id=AA003AUL
AEchem Scientific Corp., USA	AE1-016088	http://www.aechemsc.com/info_products/AE1-016088.php
AHH Chemical co.,ltd	MT-18718	http://www.ahhchemical.com/product/MT-18718.html
AK Scientific, Inc. (AKSCI)	H972	http://www.aksci.com/item_detail.php?cat=H972
Aaron Chemicals	AR003BMD	http://www.aaronchem.com/83-43-2
AbMole Bioscience	M3468	http://www.abmole.com/products/methylprednisolone.html
Acadechem	ACDS-065513	http://www.acadechemical.com/product/140212
Achemtek	0104-014278	http://www.achemtek.com/83-43-2
Acorn PharmaTech	ACN-037579	http://www.acornpharmatech.com/
Acros Organics	AC338800010	https://www.fishersci.com/shop/products/6-methylprednisolone-acros-organics-1/AC338800010
Acros Organics	AC338800050	https://www.fishersci.com/shop/products/6-methylprednisolone-acros-organics-2/AC338800050
Alfa Chemistry	ACM83432	https://www.alfa-chemistry.com/methylprednisolone-cas-83-43-2-item-106534.htm
Alsachim	3316	http://www.alsachim.com/product-C4602-glo.bal-view.html
ApexBio Technology	A4233	http://www.apexbt.com/methylprednisolone-16832.html
Aurora Fine Chemicals LLC	A17.894.462	http://online.aurorafinechemicals.com/info?ID=A17.894.462
AvaChem Scientific	2802	http://www.avachem.com/productSearch.asp?2802
Axon MedChem	2066	https://www.axonmedchem.com/product/2066
BioCrick	BCC2256	http://www.biocrick.com/Methylprednisolone-BCC2256.html
BioSynth	Q-201395	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-201395.html
Chem Scene	CS-2246	http://www.chemscene.com/83-43-2.html
ChemMol	99160511	http://www.chemmol.com/chemmol/99160511.html
Chemspace	CSSB00000042994	https://chem-space.com/CSSB00000042994
Combi-Blocks	QH-6553	http://www.combi-blocks.com/cgi-bin/find.cgi?QH-6553
DC Chemicals	DCAPI1359	http://www.dcchemicals.com//product_show-Methylprednisolone.html
Glentham Life Sciences	GP2286	http://www.glentham.com/products/product/GP2286/
LGC Standards	DRE-C15141700	https://www.lgcstandards.com/US/en/p/DRE-C15141700
LGC Standards	DRE-XA15141700AL	https://www.lgcstandards.com/US/en/p/DRE-XA15141700AL
LGC Standards	LGCFOR0190.00	https://www.lgcstandards.com/US/en/p/LGCFOR0190.00
LGC Standards	MM0190.00-0250	https://www.lgcstandards.com/US/en/p/MM0190.00-0250
Lab Network	LN00366059	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00366059
MedChem Express	HY-B0260	https://www.medchemexpress.com/methylprednisolone.html
OChem	4193	http://www.ocheminc.com/index.php?act=psearch&pid=010M591
Parchem	29400	http://www.parchem.com/chemical-supplier-distributor/Methylprednisolone-019400.aspx
Parchem	29401	http://www.parchem.com/chemical-supplier-distributor/Methylprednisolone-019401.aspx
Parchem	29406	http://www.parchem.com/chemical-supplier-distributor/Methylprednisolone-Sodium-Succinate-019406.aspx
Parchem	29407	http://www.parchem.com/chemical-supplier-distributor/Methylprednisolone-Sodium-Succinate-019407.aspx
Sigma-Aldrich	46436_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/46436?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	BP248_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp248?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	M1750000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/m1750000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	M0639_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/m0639?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1435003_USP	https://www.sigmaaldrich.com/catalog/product/usp/1435003?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S049856	http://www.sinfoobiotech.com/product/1053254
Smolecule	S535227	http://www.smolecule.com/products/s535227
TCI (Tokyo Chemical Industry)	M1665	http://www.tcichemicals.com/eshop/en/us/commodity/M1665/index.html
THE BioTek	bt-275679	https://www.thebiotek.com/product/inhibitors/bt-275679
Tocris	4819	https://www.tocris.com/products/methylprednisolone_4819
eNovation Chemicals	D628826	https://www.enovationchem.com/ProductDetails.asp?ProductID=D628826
eNovation Chemicals	D674504	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674504
eNovation Chemicals	D767281	https://www.enovationchem.com/ProductDetails.asp?ProductID=D767281
iChemical	EBD27626	http://www.ichemical.com/products/83-43-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Corticosteroids for acute severe asthma in hospitalised patients.	2001	11279726
Sensorineural hearing loss in conjunction with aortic insufficiency in systemic lupus erythematosus.	2001	11252692
Reversible posterior leukoencephalopathy in a patient with minimal-change nephrotic syndrome.	2001 Apr	11273900
Lupus nephritis in a child with AIDS.	2001 Apr	11273897
Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus.	2001 Apr	11247869
Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins.	2001 Feb	11275464
Initial remission-inducing effect of very low-dose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japanese adults.	2001 Feb	11269678
Severe renal impairment in the case of classic polyarteritis nodosa.	2001 Feb	11261683
Three cases of C-ANCA-positive vasculitis treated with immunoadsorption: possible benefit in early treatment.	2001 Feb	11258615
Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis.	2001 Feb	11257152
Steroid-resistant kidney transplant rejection: diagnosis and treatment.	2001 Feb	11251032
Selective involvement of the choroid plexus on cerebral magnetic resonance images: a new radiological sign in patients with systemic lupus erythematosus with neurological symptoms.	2001 Feb	11246685
[Contact allergy caused by poison ivy (Toxicodendron spp].	2001 Feb	11244892
Lupus nephritis in children: prognostic significance of clinicopathological findings.	2001 Feb	11244305
[Psychological and behavioral disorders with good outcome in neurosarcoidosis].	2001 Feb	11234677
[Value of abdominal-pelvic computed tomography in adult rheumatoid purpura].	2001 Feb	11234671
Preliminary results of a prospective randomized study of basiliximab in kidney transplantation.	2001 Feb-Mar	11267613
Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation.	2001 Feb-Mar	11267566
Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation.	2001 Feb-Mar	11267411
Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation.	2001 Feb-Mar	11267396
Daclizumab induction therapy in combination with tacrolimus.	2001 Feb-Mar	11267354
Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations.	2001 Feb-Mar	11267319
Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation.	2001 Feb-Mar	11267285
Successful withdrawal of steroid after renal transplantation.	2001 Feb-Mar	11267272
Prevention of bone loss in kidney graft recipients.	2001 Feb-Mar	11267228
Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients.	2001 Feb-Mar	11267179
Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.	2001 Feb-Mar	11267169
Addition of steroids blocks the tolerogenic potential of donor-specific blood transfusion.	2001 Feb-Mar	11266868
Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue.	2001 Jan	11281396
A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease.	2001 Jan	11244437
Recurrent orbital inflammation from metastatic orbital carcinoid tumor.	2001 Mar	11281589
[Intramural hematoma of the large intestine caused by cytomegalovirus vasculitis in a patient with SLE].	2001 Mar	11280907
Pulmonary function in men after repeated sessions of oxygen breathing at 0.25 MPa for 90 min.	2001 Mar	11277287
[Value of methylprednisolone perfusions in the corticodependent forms of Horton's disease].	2001 Mar	11270276
[Acute myelitis of an unusual cause in a child: the lymphocytic choriomeningitis virus].	2001 Mar	11270252
Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes.	2001 Mar	11263768
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.	2001 Mar	11260088
Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.	2001 Mar	11244163
Chronic eosinophilic pneumonia presenting with recurrent massive bilateral pleural effusion : case report.	2001 Mar	11243986
Systemic glucocorticoids in severe exacerbations of COPD.	2001 Mar	11243949
Steroids for acute exacerbations of COPD : how long is enough?	2001 Mar	11243937
Methylprednisolone does not benefit patients undergoing coronary artery bypass grafting and early tracheal extubation.	2001 Mar	11241092
Intrathecal methylprednisolone for postherpetic neuralgia.	2001 Mar 29	11280324
Intrathecal methylprednisolone for postherpetic neuralgia.	2001 Mar 29	11280323
Intrathecal methylprednisolone for postherpetic neuralgia.	2001 Mar 29	11280322
Intrathecal methylprednisolone for postherpetic neuralgia.	2001 Mar 29	11280321
Intrathecal methylprednisolone for postherpetic neuralgia.	2001 Mar 29	11280320
Intrathecal methylprednisolone for postherpetic neuralgia.	2001 Mar 29	11280319
[Comparison of two different treatments of lateral humeral epicondylitis--"tennis elbow". A randomized controlled trial].	2001 Mar 5	11257751
Prospective experience with a 20-gauge Tuohy needle for lumbar epidural steroid injections: Is confirmation with fluoroscopy necessary?	2001 Mar-Apr	11251138

Patents

Sample Use Guides

In Vivo Use Guide

Each Medrol Tablet (methylprednisolone) for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of methylprednisolone. The initial dosage of Medrol Tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated.

Route of Administration: Other

In Vitro Use Guide

Treatment with methylprednisolone concentrations above 50 uM could ignificantly reduce the proliferation activity of human CLL cell line MEC-1 by 23.34%, 30.73%, 30.57% after 24 h, and 28.48%, 42.35%, 44.56% after 48 h respectively

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:20:44 GMT 2023` Edited by `admin` on `Fri Dec 15 15:20:44 GMT 2023`
Record UNII	5GMR90S4KN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

METHYLPREDNISOLONE HEMISUCCINATE

Common Name

English

METHYLPREDNISOLONE HYDROGEN SUCCINATE

Common Name

English

METHYLPREDNISOLONE HEMISUCCINATE [USP-RS]

Common Name

English

METHYLPREDNISOLONE HEMISUCCINATE [USP MONOGRAPH]

Common Name

English

METHYLPREDNISOLONE HYDROGEN SUCCINATE [MART.]

Common Name

English

METHYLPREDNISOLONE SUCCINATE [JAN]

Common Name

English

6-METHYLPREDNISOLONE-21-HEMISUCCINATE

Common Name

English

METHYLPREDNISOLONE SUCCINATE

Common Name

English

Methylprednisolone hemisuccinate [WHO-DD]

Common Name

English

METHYLPREDNISOLONE HEMISUCCINATE [USP IMPURITY]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C521